Compass pathways stock forecast.
Compass Pathways has also returned positive data from a Phase 2 trial of its psilocybin formulation, using a similar "monitored sessions" approach, even providing music, soft furnishings and a ...
CMPS Earnings Date and Information. COMPASS Pathways last posted its quarterly earnings data on November 2nd, 2023. The reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by $0.17. COMPASS Pathways has generated ($2.59) earnings per share over the last year ( ($2.59) diluted …WebCompass Pathways to participate in upcoming Evercore investor conference. LONDON, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will hold a fireside chat …Compass Pathways has released the strongest evidence yet that psilocybin can improve outcomes in patients with treatment-resistant depression, linking its COMP360 candidate to a sharp improvement ...The Compass Pathways Plc (CMPS) stock price forecast for the next 12 months is generally positive, with an average analyst price target of $20.62, representing a +291.30% increase from the current price of $5.27. The highest analyst price target is $35.17, and the lowest is $6.0744.
COMPASS Pathways's market cap is currently ―. The company's EPS TTM is $-1.981; its P/E ratio is -2.86; COMPASS Pathways is scheduled to report earnings on March 4, 2024, and the estimated EPS forecast is $-0.34. See an overview of income statement, balance sheet, and cash flow financials. Dec 22. Sep 22.May 25, 2021 · Learn More. Market Cap. (-2.86%) -$0.17. Current Price. The biotech is developing a treatment paradigm combining talk therapy with a purified version of psilocybin, the active ingredient in "magic ... Aug 26, 2023 · Beam Therapeutics (BEAM-1.72%), COMPASS Pathways (CMPS-6.05%), ... The average price target for the stock is $41.67, implying a 382% upside potential from its current share price. Like Beam ...
COMPASS Pathways PLC ADR analyst ratings, historical stock prices, earnings estimates & actuals. CMPS updated stock price target summary. Despite the potential of EVgo, Inc. (EVGO), Amyris, Inc. (AMRS), and COMPASS Pathways plc (CMPS) springing a surprise during the earnings season, their less-than-ideal fundamentals deem it wise to avoid placing any long-term bets on these heavily shorted stocks.In 2021, easy money, unprecedented hype created by retail …
3 พ.ค. 2564 ... Did you miss out on being an early investor in the Cannabis Boom? Investing in Compass Pathways stock ($CMPS) may be your golden ticket.UK-based COMPASS Pathways recently published data from its Phase IIb trials, with COMP360 psilocybin therapy for treatment-resistant depression. This follows the release of the design for the company’s pivotal Phase III trials, the first-ever Phase III psilocybin therapy trial and the final studies prior to market approval. With the treatment’s …What is the current Price Target and Forecast for COMPASS Pathways (CMPS) COMPASS Pathways (CMPS) (Real Time Quote from BATS) $5.93 USD +0.10 …COMPASS Pathways (NASDAQ: CMPS) has seen its earnings outlook for FY2023 revised by Cantor Fitzgerald. The equities researchers at Cantor Fitzgerald have raised their EPS estimates, predicting that the company will now earn ($2.08) per share for the year, up from their previous forecast of ($2.24).Dec 2, 2023 · The stock spiked 2.01% in intraday trading to $6.10 this Friday, 12/01/23, hitting a weekly high. The stock’s 5-day price performance is -5.43%, and it has moved by 5.54% in 30 days. Based on these gigs, the overall price performance for the year is -40.78%. The short interest in Compass Pathways Plc ADR (NASDAQ:CMPS) is 3.91 million shares ...
2 พ.ย. 2566 ... Stock FTCH logo. FTCH · Farfetch Will Not Announce Third Quarter 2023 ... price prior to the financing, and will be exercisable at the election ...
Mar 2, 2022 · COMP360 Overview (August Company Presentation) Psilocybin is a hallucinogenic chemical found in psychedelic mushrooms. It also is in Phase II clinical trials for the treatment of post-traumatic ...
The latest price target for Compass Pathways ( NASDAQ: CMPS) was reported by Cantor Fitzgerald on Tuesday, August 22, 2023. The analyst firm set a price target for 21.00 expecting CMPS to rise to ...WebMarket Activity. Funds + ETFs. Analyst ratings can be used in addition to other personal research work prior to making investment decisions. Do Not Sell My Personal Information (CA Residents Only ...Stock Price Forecast. The 9 analysts offering 12-month price forecasts for Compass Inc have a median target of 2.70, with a high estimate of 5.00 and a low estimate of 2.00. The median estimate ...WebMarket Activity. Funds + ETFs. Analyst ratings can be used in addition to other personal research work prior to making investment decisions. Do Not Sell My Personal Information (CA Residents Only ... Stock Price Forecast. The 5 analysts offering 12-month price forecasts for Compass Pathways PLC have a median target of 38.00, with a high estimate of 120.00 and a low estimate of 22.00. The median estimate represents a +488.24% increase from the last price of 6.46.
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies, and are pioneering the development of a ... A live webcast of the call will be available on COMPASS Pathway’s website at: First Quarter 2023 Financial Results. The webcast will also be available on the Investors section of the COMPASS Pathways website. The webcast will be archived for 30 days. The call will also be webcast on the COMPASS Pathways website and archived for 30 days.WebDec 1, 2023 · COMPASS Pathways (CMPS) Stock Forecast & Price Target $6.05 +0.22 (+3.77%) (As of 11/22/2023 ET) Compare Today's Range $5.80 $6.07 50-Day Range $5.27 $9.92 52-Week Range $5.01 $11.48 Volume 169,831 shs Average Volume 347,447 shs Market Capitalization $374.50 million P/E Ratio N/A Dividend Yield N/A Price Target $46.83 Compass Pathways Plc stock forecasts for 2023-2027. Date: Open Price: Close Price: Change: Compass Pathways Plc Stock Forecast for 2023: January 2023: 2.04: 1.02-50% ...That's true for all of the existing public psychedelic biotechs engaged in drug development, including such industry leaders as Compass Pathways (CMPS-2.26%) and Atai Life Sciences (ATAI-1.51% ...Wall Street Stock Market & Finance report, prediction for the future: You'll find the Compass Pathways Plc - ADR share forecasts, stock quote and buy / sell signals below. According to present data Compass Pathways Plc - ADR's CMPS shares and potentially its market environment have been in bearish cycle last 12 months (if exists).It is one of the best psychedelic stocks to invest in. On December 15, EF Hutton analyst Elemer Piros initiated coverage of COMPASS Pathways plc (NASDAQ:CMPS) with a Buy rating and a $38 price target.
Latest CMPS News. View. COMPASS Pathways (CMPS, $5.98) entered Downtrend as Momentum indicator drops below 0 level on Nov 30, 2023. Tickeron - Stocks • 3 days ago. Compass Pathways to participate in upcoming Evercore investor conference. Globe Newswire • 10 days ago.
A. While ratings are subjective and will change, the latest Compass Pathways ( CMPS) rating was a reiterated with a price target of $0.00 to $21.00. The current price Compass Pathways ( CMPS) is ...COMPASS Pathways PLC ADR analyst ratings, historical stock prices, earnings estimates & actuals. CMPS updated stock price target summary. Market Activity. Funds + ETFs. Analyst ratings can be used in addition to other personal research work prior to making investment decisions. Do Not Sell My Personal Information (CA Residents Only ... LONDON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that new positive data demonstrating the potential of COMP360 psilocybin therapy in depression have …COMPASS Pathways is a business that is trying to treat a serious form of depression ... Patents, Financials, and Forecast. COMPASS is pre ... COMPASS Pathways is an extremely risky stock, ...Find the latest COMPASS Pathways Plc - American CMPS analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Date Range. investment rating ...Web
Compass Pathways jumped in its first day of trading on Friday, making it the first psychedelic drug company to go public on a big U.S. exchange.. X. Shares surged 70.6% to close at 29.00 in the ...
10 stocks we like better than Compass Pathways Plc When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor ...
We are Compass Pathways, a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. News & events. News releases. SEC filings & annual reports. Our annual review. Stock information. Stock quote & chart. Historical price lookup. Corporate governance.WebNonetheless, Atai remains one of the leaders in the psychedelics segment of the biotech industry, and it holds a 22.4% stake in Compass Pathways, which is one of the other leaders. So if Compass ...WebNov 29, 2023 · About CMPS. COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. On March 3, 2023 the AMA published the Summary of Panel Actions which included the acceptance of the new CPT III code. The application was titled, “Continuous In-Person Monitoring and Intervention during Psychedelic Medication Therapy.”. CPT III codes are a set of temporary codes assigned to emerging technologies, services and procedures.13 de mar. de 2023 ... Analysts at Canaccord Genuity (TSX:CF, LSE:CF) have reiterated their 'Buy' rating and US$60 price target for COMPASS Pathways after the ...COMPASS Pathways plc (CMPS) latest earnings report: revenue, EPS, surprise, history, news and analysis.Stock analysis for Compass Pathways Plc (CMPS:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Latest CMPS News. View. COMPASS Pathways (CMPS, $5.98) entered Downtrend as Momentum indicator drops below 0 level on Nov 30, 2023. Tickeron - Stocks • 3 days ago. Compass Pathways to participate in upcoming Evercore investor conference. Globe Newswire • 10 days ago.Key Points. Cathie Wood is an icon in the world of disruptive tech. Her firm ARK Invest holds positions in Beam Therapeutics, COMPASS Pathways, and 908 Devices. Wall Street analysts have ...AnaptysBio presently has a consensus target price of $29.00, suggesting a potential upside of 105.09%. COMPASS Pathways has a consensus target price of $46.83, suggesting a potential upside of 683.17%. Given AnaptysBio's stronger consensus rating and higher probable upside, analysts plainly believe COMPASS Pathways is more …According to 11 analyst offering 12-month price targets in the last 3 months, Compass Pathways has an average price target of $56.82 with a high of $120.00 and a low of $21.00.Web2 พ.ย. 2566 ... Each share of common stock and accompanying common warrant to purchase one share of common stock are being sold at a combined price to the ...
Oct 22, 2021 · And the biotechnology industry's average price-to-sales multiple is 4.7. Thus, if Compass manages to capture a mere 10% of that per year, it could be bringing in $139 million in revenue. Assuming ... 10 stocks we like better than Compass Pathways Plc When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor ...People use statistics daily for weather forecasts, predicting disease, preparing for emergencies, medical research, political campaigns, tracking sales, genetics, insurance, the stock market and quality testing.Instagram:https://instagram. mortgage lender texasautomated trading botsbest rated gold and silver dealershybrid kia telluride Key Points. Cathie Wood is an icon in the world of disruptive tech. Her firm ARK Invest holds positions in Beam Therapeutics, COMPASS Pathways, and 908 Devices. Wall Street analysts have ...(Note: COMPASS stock price on Nasdaq jumped between June 30 and July 5, going from $8.10 to currently trading at $8.80 following highest at $9.02 also today, July 5 shortly after opening and ... 1964 silver 50 cent piece valuebest tax software self employed Currently 16 wall-street analysts regularly analyze the financials of Compass Pathways Plc on a frequent basis to provide recommendations along with target share price. 16 analysts offering 12-month price forecasts for Compass Pathways Plc (CMPS) have a share price target of $42.13.Web td ameritrade metatrader 4 In August 2023 COMPASS Pathways announced a major private placement that initially eased concerns regarding group’s cash runway. Find out why CMPS stock is a Sell.16 ส.ค. 2566 ... ... Price” requirement (as defined in the Nasdaq rules). COMPASS intends to use the net proceeds from the proposed financing to fund its pivotal ...The upgrade of COMPASS Pathways PLC Sponsored ADR to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move ...